Evidence of the principle of similitude in modern fatal iatrogenic events

M.Z. Teixeira

doi:10.1016/j.homp.2006.06.004

Homeopathy, Inhaltsverzeichnis

Homeopathy 2006; 95(04): 229-236
DOI: 10.1016/j.homp.2006.06.004

Education and Debate

Evidence of the principle of similitude in modern fatal iatrogenic events

Autor*innen

M.Z. Teixeira

Verantwortlicher Herausgeber dieser Rubrik:

Abstract

Samuel Hahnemann attributed fundamental importance to the principle of similitude, promoting it to a ‘natural law’. Observing that enantiopathic or allopathic treatment produced enduring aggravation of the disease symptoms after a brief and transitory initial relief, he systematised homeopathic treatment, prescribing substances that provoke similar symptoms in healthy individual. Based on clinical and experimental observations, he anticipated the concept of homeostasis, dividing the effects of substances into: primary action of the medicine followed by secondary action or reaction of the organism. This reaction, known as the rebound effect or paradoxical action by modern pharmacology, used to awake the curative response of the body when the principle of similitude is applied, is responsible for several iatrogenic diseases when used on the basis of the principle of contraries. This study discusses the role of this paradoxical reaction of the organism in the fatal side effects of four important drugs, used according to the model of enantiopathic treatment of the symptoms. I present evidence relating to acetylsalicylic acid, rofecoxib, antidepressants and long-acting bronchodilators. The consequences of the allopathic treatment could be decreased if health professionals valued homeostasis, minimising the rebound effect of the organism by gradual suspension of palliative drugs.

Keywords

similitude - homeostasis - rebound effect - paradoxical reaction - compensatory response - fatal iatrogenic event

Volltext

Referenzen

References
1 Hahnemann S. Organon of Medicine, 6th Edn. (Translated by William Boericke). New Delhi: B Jain Publishers, 1991.
2 Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica [Similar cures similar: the homoeopathic cure principle based by the medical and scientific rationality]. São Paulo: Editorial Petrus; 1998.
3 Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 1999; 88: 112-120.
4 Teixeira M.Z. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses 2003; 60: 276-283.
5 Teixeira M.Z. Paradoxical strategy for treating chronic diseases: a therapeutic model used in homeopathy for more than two centuries. Homeopathy 2005; 94: 265-266.
6 Ardelt W., Pasold K., Hillemanns H.G. Side effects of drug for thromboembolism prophylaxis. Results from the University Women's Clinic Freiburg/Br. Fortschr Med 1979; 97: 471-474.
7 Terashita Z., Imura Y., Tanabe M. et al. CV-4151—a potent, selective thromboxane A2 synthetase inhibitor. Thromb Res 1986; 41: 223-237.
8 Averkov O.V., Zateishchikov D.A., Gratsianskii N.A., Logutov Iu.A., Iavelov I.S., Ianus V. Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study). Kardiologiia 1993; 33: 4-9.
9 Mousa S.A., Forsythe M.S., Bozarth J.M., Reilly T.M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 1993; 83: 367-373.
10 Beving H., Eksborg S., Malmgren R.S., Nordlander R., Ryden L., Olsson P. Inter-individual variations of the effect of low dose aspirin regime on platelet cyclooxygenase activity. Thromb Res 1994; 74: 39-51.
11 Raskob G.E., Durica S.S., Morrissey J.H., Owen W.L., Comp P.C. Effect of treatment with low-dose warfarin–aspirin on activated factor VII. Blood 1995; 85: 3034-3039.
12 Col J. Current point of view on medical treatment of unstable angina. Arch Mal Coeur Vaiss 1996; Spec (5): 15-18.
13 Schulman S.P., Goldschmidt-Clermont P.J., Topol E.J. et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996; 94: 2083-2089.
14 Aguejouf O., Belougne-Malfati E., Doutremepuich F., Belon P., Doutremepuich C. Tromboembolic complications several days after a single-dose administration of aspirin. Thromb Res 1998; 89: 123-127.
15 Main C., Palmer S., Griffin S. et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-156.
16 Doutremepuich C., Aguejouf O., Pintigny D., Sertillanges M.N., De Seze O. Thrombogenic properties of ultra-low-dose of acetylsalicylic acid in a vessel model of laser-induced thrombus formation. Thromb Res 1994; 76: 225-229.
17 Doutremepuich C.H., Aguejouf O., Belon P. Effects of ultra-low dose aspirin on embolization in a model of laser-induced thrombus formation. Semin Thromb Hemost 1996; 22 (Suppl. 01) 67-70.
18 Aguejouf O., Malfatti E., Belon P., Doutremepuich C. Effects of acetyl salicylic acid therapy on an experimental thrombosis induced by laser beam. Thromb Res 2000; 99: 595-602.
19 Belougne-Malfatti E., Aguejouf O., Doutremepuich F., Belon P., Doutremepuich C. Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. Thromb Res 1998; 90: 215-221.
20 Doutremepuich C., Aguejouf O., Malfatti E., Belon P. Time related neutralization of two doses acetyl salicylic acid. Thromb Res 2000; 100: 317-323.
21 Doutremepuich C., Pailley D., Anne M.C., De Seze O., Paccalin J., Quilichini R. Template bleeding time after ingestion of ultra-low doses of acetylsalicylic acid in healthy subjects. Preliminary study. Thromb Res 1987; 48: 501-504.
22 Doutremepuich C., De Seze O., Le Roy D., Lalanne M.C., Anne M.C. Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, platelet aggregation and coagulation. Haemostasis 1990; 20: 99-105.
23 Lalanne M.C., Doutremepuich C., de Seze O., Belon P. What is the effect of acetylsalicylic acid at ultra low dose on the interaction platelets/vessel wall?. Thromb Res 1990; 60: 231-236.
24 Ferrari E., Benhamou M., Cerboni P., Baudouy M. Coronary syndromes following aspirin withdrawal. 69ª Annual International Scientific Assembly of The American College of Chest Physicians, Orlando, EUA, 2003. CHEST 2003; 124: 148S.
25 Ferrari E., Benhamou M., Cerboni P., Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459.
26 Aetna InteliHealth, Harvard Medical School. Health News: Aspirin withdrawal may pose risk to coronary patients. Available on: 〈 http://www.intelihealth.com/IH/ihtIH/WSAZR000/333/341/371250.html 〉.
27 Maulaz A.B., Bezerra D.C., Michel P., Bogousslavsky J. Effect of discountinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62: 1217-1220.
28 Andrioli G., Lussignoli S., Ortolani R., Minuz P., Vella F., Bellavite P. Dual effects of diclofenac on human platelet adhesion in vitro. Blood Coagul Fibrinolysis 1996; 7: 153-156.
29 Andrioli G., Lussignoli S., Gaino S., Benoni G., Bellavite P. Study on paradoxical effects of NSAIDs on platelet activation. Inflammation 1997; 21: 519-530.
30 Fischer L.M., Schlienger R.G., Matter C.M., Jick H., Meier C.R. Discontinuation of nonsteroidal anti-inflammatory drugs is associated with an increased risk of acute myocardial infarction. Arch Intern Med 2004; 164: 2472-2476.
31 Sibon I., Orgogozo J.M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62: 1187-1189.
32 Nelson M.R., Liew D., Bertram M., Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged>or=70. BMJ 2005; 330: 1306.
33 Pijak M.R. Rebound inflammation and the risk of ischemic stroke after discontinuation of aspirin therapy. Arch Neurol 2006; 63: 300-301.
34 Griffin M.R., Stein C.M., Graham D.J., Daugherty J.R., Arbogast P.G., Ray W.A. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 2004; 13: 339-343.
35 Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
36 Graham D.J., Campen D., Hui R. et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 2005; 365: 475-481.
37 Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case–control analysis. BMJ 2005; 330: 1366.
38 Ray W.A., Stein C.M., Daugherty J.R., Hall K., Arbogast P.G., Griffin M.R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
39 Johnsen S.P., Larsson H., Tarone R.E. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch Intern Med 2005; 165: 978-984.
40 Levesque L.E., Brophy J.M., Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481-489.
41 Levesque L.E., Brophy J.M., Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006; 174: 1563-1569.
42 Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
43 Jureidini J.N., Doecke C.J., Mansfield P.R., Haby M.M., Menkes D.B., Tonkin A.L. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879-883.
44 Culpepper L., Davidson J.R., Dietrich A.J., Goodman W.K., Kroenke K., Schwenk T.L. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry 2004; 65: 742-749.
45 Jick H., Kaye J.A., Jick S.S. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338-343.
46 Leon A.C., Marzuk P.M., Tardiff K., Teres J.J. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004; 65: 915-918.
47 Gunnell D., Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004; 329: 34-38.
48 Lenzer J. Secret US report surfaces on antidepressants in children. BMJ 2004; 329: 307.
49 Nelson R. Antidepressant use in children—safe or not? Hiding unfavorable data makes it hard to know. Am J Nurs 2004; 104: 25-26.
50 US Food and Drug Administration. FDA Public Health Advisory (October 15, 2004): “Suicidality in children and adolescents being treated with antidepressant medications”. Available on: 〈 http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm 〉.
51 US Food and Drug Administration. FDA Public Health Advisory (June 30, 2005): ‘Suicidality in adults being treated with antidepressant Medications’. Available on: 〈 http://www.fda.gov/cder/drug/advisory/SSRI200507.htm 〉.
52 Aetna InteliHealth, Harvard Medical School. Health News: FDA warns of suicide risk for Paxil. Available on: 〈 http://www.intelihealth.com/IH/ihtIH/EMIHC000/333/8014/466054.html 〉.
53 Spencer T.J., Biederman J., Wilens T.E., Faraone S.V. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002; 63 (Suppl. 12) 16-22.
54 Hesse L.M., Von Moltke L.L., Greenblatt D.J. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003; 17: 513-532.
55 Wichniak A., Brunner H., Ising M., Pedrosa Gil F., Holsboer F., Friess E. Impaired hypothalamic–pituitary–adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. Psychoneuroendocrinology 2004; 29: 1101-1108.
56 Verdoux H., Bourgeois M. [Short-term sequelae of lithium discontinuation]. Encephale 1993; 19: 645-650.
57 Steiger A., Benkert O., Holsboer F. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men. Neuropsychobiology 1994; 30: 101-105.
58 Feige B., Voderholzer U., Riemann D., Dittmann R., Hohagen F., Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 2002; 26: 246-258.
59 D’Aquila P.S., Peana A.T., Panin F., Grixoni C., Cossu M., Serra G. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur J Pharmacol 2003; 458: 129-134.
60 D’Aquila P.S., Panin F., Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur J Pharmacol 2004; 492: 61-63.
61 Verster J.C., Volkerts E.R. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 2004; 10: 45-76.
62 Lerman C., Niaura R., Collins B.N. et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 2004; 18: 362-366.
63 Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 1997; 56: 455-462.
64 Feige B., Voderholzer U., Riemann D., Dittmann R., Hohagen F., Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 2002; 26: 246-258.
65 Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 1997; 56: 455-462.
66 Pace-Schott E.F., Gersh T., Silvestri R., Stickgold R., Salzman C., Hobson J.A. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001; 10: 129-142.
67 Gervasoni D., Panconi E., Henninot V. et al. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine. Pharmacol Biochem Behav 2002; 73: 557-563.
68 De Oliveira R.A., Cunha G.M., Borges K.D. et al. The effect of venlafaxine on behaviour, body weight and striatal monoamine levels on sleep-deprived female rats. Pharmacol Biochem Behav 2004; 79: 499-506.
69 Stolley P.D. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972; 105: 883-890.
70 Aellig W.H. Pindolol—a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol 1982; 13 (Suppl. 02) 187S-192S.
71 Newcomb R., Tashkin D.P., Hui K.K., Conolly M.E., Lee E., Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. Am Rev Respir Dis 1985; 132: 12-15.
72 Vathenen A.S., Knox A.J., Higgins B.G., Britton J.R., Tattersfield A.E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554-558.
73 Svedmyr N. Action of corticosteroids on beta-adrenergic receptors. Clinical aspects. Am Rev Respir Dis 1990; 141 2, Part 2 S31-S38.
74 Cochrane G.M. Bronchial asthma and the role of beta 2-agonists. Lung 1990; 168 (Suppl. 01) 66-70.
75 Svedmyr N. The current place of beta 2-agonists in the management of asthma. Lung 1990; 168 (Suppl. 01) 105-110.
76 Mintzer M.J. Asthma therapy: present trends and future prospects. Compr Ther 1990; 16: 12-16.
77 Beach R., Young C.L., Harkawat R. et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155-157.
78 Yates D.H., Sussman H.S., Shaw M.J., Barnes P.J., Chung K.F. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152 4, Part 1 1170-1174.
79 De Jong J.W., van der Mark T.W., Koeter G.H., Postma D.S. Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. Am J Respir Crit Care Med 1996; 153: 70-75.
80 Kozlik-Feldmann R., von Berg A., Berdel D., Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. Eur J Med Res 1996; 1: 465-470.
81 Wilding P.J., Clark M.M., Oborne J., Bennett J.A., Tattersfield A.E. Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 1996; 51: 989-992.
82 Bennett J.A., Thompson Coon J., Pavord I.D., Wilding P.J., Tattersfield A.E. The airway effects of stopping regular oral theophylline in patients with asthma. Br J Clin Pharmacol 1998; 45: 402-404.
83 Hancox R.J., Cowan J.O., Flannery E.M., Herbison G.P., McLachlan C.R., Taylor D.R. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med 2000; 94: 767-771.
84 Farmer P., Pugin J. Beta-adrenergic agonists exert their ‘anti-inflammatory’ effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000; 279: L675-L682.
85 Van Schayck C.P., Cloosterman S.G., Bijl-Hofland I.D., Van den Hoogen H., Folgering H.T., Van Weel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respir Med 2002; 96: 155-162.
86 US Food and Drug Administration. FDA Public Health Advisory: ‘Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder)’. Available on: 〈 http://www.fda.gov/cder/drug/advisory/LABA.htm 〉.
87 Knobil K., Yancey S., Kral K., Rickard K. Salmeterol multi-center asthma research trial (SMART): results from an interim analysis. 69ª Annual International Scientific Assembly of The American College of Chest Physicians, Orlando, EUA, 2003. CHEST 2003; 124: 335S.
88 US Food and Drug Administration. The FDA Safety Information and Adverse Event Reporting Program: 2003 Safety Alert—Serevent (salmeterol xinafoate). Available on: 〈 http://www.fda.gov/medwatch/SAFETY/2003/serevent.htm 〉.
89 Health Canada. Advisory 2005-107, October 4, 2005: Safety information about a class of asthma drugs known as long-acting beta-2 agonists. Available on: 〈 http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2005/2005_107_e.html 〉.
90 Lurie P., Wolfe S.M. Misleading data analyses in salmeterol (SMART) study. Lancet 2005; 366: 1261-1262 discussion 1262.
91 Peper A. A theory of drug tolerance and dependence I: a conceptual analysis. J Theor Biol 2004; 229: 477-490.
92 Peper A. A theory of drug tolerance and dependence II: the mathematical model. J Theor Biol 2004; 229: 491-500.